RWLK REWALK ROBOTICS LTD

German Federal Social Court Schedules Hearing on Classification of Exoskeleton Medical Devices for Spinal Cord Injured Individuals

German Federal Social Court Schedules Hearing on Classification of Exoskeleton Medical Devices for Spinal Cord Injured Individuals

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the German Federal Social Court has scheduled a hearing to review the decision of whether an exoskeleton medical device should be classified as directly or indirectly compensating for the lost function of individuals with spinal cord injuries or paraplegia. The hearing is scheduled for November 10, 2022.

The court’s decision will establish a new national policy for exoskeleton medical aids and will apply nationally to all Germans covered by Statutory Health Insurance (SHI). Establishing a legal classification for exoskeletons will provide guidance for both patients and insurance companies, setting a reliable legal basis for the application process for the provision of exoskeletons.

"The multitude of benefits that patients experience from regaining the ability to stand and walk again with the use of a ReWalk exoskeleton have made it clear that restoring walking function after spinal cord injury is a basic need,” says Larry Jasinski, CEO of ReWalk Robotics. “The German healthcare system has led the way in its adoption of exoskeletons for spinal cord injured individuals. By establishing a clear classification for exoskeleton medical aids, the court will provide important, national guidance to payers and patients in the application process for care and create a pathway to providing access to this innovative technology for all eligible users in Germany through an established supply process. We look forward to the upcoming decision.”

For more information on ReWalk Robotics and the ReWalk exoskeleton, visit .

About ReWalk Robotics Ltd.



ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit rewalk.com.



ReStore® is a registered trademark of ReWalk Robotics Ltd. in the United States, Europe and the United Kingdom.

Forward-Looking Statements



In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in ReWalk’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in ReWalk's annual report on Form 10-K and 10-K/A for the year ended December 31, 2021 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Investor Contact:

Almog Adar

Director of Finance

ReWalk Robotics Ltd.

T:

E:

Media Contact:

John Tomlin

E:



EN
12/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Ltd. Reports Second Quarter 2025 Financial Results

Lifeward Ltd. Reports Second Quarter 2025 Financial Results Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations o...

 PRESS RELEASE

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadersh...

Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company’s Vice President of Finance and Chief Accounting Officer, has been appointed as the Company’s new Chief Financial Officer. "I am thrilled to welcome Almog to the executive leadership t...

 PRESS RELEASE

Lifeward to Report Second Quarter Financial Results on August 14, 2025

Lifeward to Report Second Quarter Financial Results on August 14, 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Vice President of Finance, will host a conferen...

 PRESS RELEASE

Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add C...

Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region Expansion adds additional AlterG dealer coverage to 6 countries throughout the Gulf Cooperation Council region MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the expansion of its relationship with SportsMed Produ...

 PRESS RELEASE

Lifeward Announces Closing of $2.6 Million Public Offering

Lifeward Announces Closing of $2.6 Million Public Offering MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch